Evidence for active drug efflux in fluoroquinolone resistance in Clostridium hathewayi

Chemotherapy

Volumn 51, Issue 5, 2005, Pages 256-262

  Rafii, Fatemeh ^a   Park, Miseon ^a   Wynne, Rebecca ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Anaerobic bacteria; Clostridium hathewayi; Efflux pump; Fluoroquinolone resistance; Multidrug transporter

Indexed keywords

ACRIFLAVINE; CIPROFLOXACIN; ETHIDIUM BROMIDE; FLEROXACIN; GLYCOPROTEIN P; LOMEFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; RHODAMINE;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL KINETICS; BACTERIAL STRAIN; CLOSTRIDIUM; DRUG ACCUMULATION; HUMAN; INTESTINE FLORA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; CLOSTRIDIUM; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; KINETICS; MEMBRANE TRANSPORT PROTEINS; NORFLOXACIN;

EID: 23944486373     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087253     Document Type: Article

References (35)

1. Aldridge KE, Ashcraft D, Bowman KA: Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes. Antimicrob Agents Chemother 1997;41:484-487.
2. Hecht DW, Wexler HM: In vitro susceptibility of anaerobes to quinolones in the United States. Clin Infect Dis 1996;23S:2-8.
3. Hecht DW: Prevalence of antibiotic resistance in anaerobic bacteria: Worrisome developments. Clin Infect Dis 2004;92-97.
4. Schaumann R, Ackermann G, Pless B, Claros MC, Rodloff AC: In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob Agents Chemother 1999;43:2783-2786.
5. Ling TKW, Liu EYM, Cheng AFB: In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates. Chemotherapy 1999;45:22-27.
6. Rafii F, Park M, Novak JS: Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother 2005;49:488-492.
7. Naber KG: Fleroxacin overview. Chemotherapy 1996;42(suppl 1):1-9.
8. Drlica K, Hooper D: Mechanism of quinolone action; in Hooper D, Rubinstein E (eds): Quinolone Antimicrobial Agents, ed 3. Washington, American Society for Microbiology, 2003, pp 19-40.
9. Yoshizumi S, Takahashi Y, Watanabe Y, Okezaki E, Ishii Y, Tateda K: In vitro antibacterial activities of new fluoroquinolones against clinical isolates of Haemophilus influenzae with ciprofloxacin-resistance-associated alterations in GyrA and ParC. Chemotherapy 2004;50:265-275.
10. Gill MJ, Brenwald NP, Wise R: Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999;43:187-189.
11. Hooper DC: Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2002;2:530-538.
12. Piddock LJ, White DJ, Gensberg K, Pumbwe L, Griggs DJ: Evidence for an efflux pump mediating multiple antibiotic resistance in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother 2000;44:3118-3121.
13. Brenwald NP, Gill MJ, Wise R: Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998;42:2032-2035.
14. Coban AY, Ekinci B, Durupinar B: A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates. Chemotherapy 2004;50:22-26.
15. Neyfakh AA, Borsch CM, Kaatz GW: Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob Agents Chemother 1993;37:128-129.
16. Kaatz GW, Seo SM, Ruble CA: Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993;37:1086-1094.
17. Poole K, Srikumar R: Multidrug efflux in Pseudomonas aeruginosa: Components, mechanisms and clinical significance. Curr Top Med Chem 2001;1:59-71.
18. Saier MH Jr: A functional-phylogenetic system for the classification of transport proteins. J Cell Biochem 1999;33(suppl 32):84-94.
19. Lomovskaya O. Watkins WJ: Efflux pumps: Their role in antibacterial drug discovery. Curr Med Chem 2001;8:1699-1711.
20. Lomovskaya O, Watkins W: Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J Mol Microbiol Biotechnol 2001;3:225-236.
21. Aeschlimann JR, Dresser LD, Kaatz GW, Rybak MJ: Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother 1999;43:335-340.
22. Brenwald NP, Gill MJ, Wise R: The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone- resistant strains of Streptococcus pneumoniae to norfloxacin. J Antimicrob Chemother 1997;40:458-460.
23. 3 Miyamae S, Nikaido H, Tanaka Y, Yoshimura F: Active efflux of norfloxacin by Bacteroides fragilis. Antimicrob Agents Chemother 1998;42:2119-2121.
24. Alexander CJ, Citron DM, Brazier JS, Goldstein EJ: Identification and antimicrobial resistance patterns of clinical isolates of Clostridium clostridioforme, Clostridium innocuum, and Clostridium ramosum compared with those of clinical isolates of Clostridium perfringens. J Clin Microbiol 1995;33:3209-3215.
25. Steer T, Collins MD, Gibson GR, Hippe H, Lawson PA: Clostridium hathewayi sp. nov., from human faeces. Syst Appl Microbiol 2001;24:353-357.
26. Woo PC, Lau SK, Woo GK, Fung AM, Yiu VP, Yuen KY: Bacteremia due to Clostridium hathewayi in a patient with acute appendicitis. J Clin Microbiol 2004;42:5947-5949.
27. Elsayed S: Human infection caused by Clostridium hathewayi. Emerg Infect Dis 2004;10:1950-1952.
28. Rafii F, Hansen EB: Isolation of nitrofurantoin-resistant mutant nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother 1998;42:1121-1126.
29. National Committee for Clinical Laboratory Standards: Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Approved Standard, ed 5. NCCLS document M11-A5, Wayne, NCCLS, 2001.
30. Baranova NN, Neyfakh AA: Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41:1396-1398.
31. Neyfakh AA: Use of fluorescent dyes as molecular probes for the study of multidrug resistance. Exp Cell Res 1988;174:168-176.
32. Chapman JS, Georgopapadakou NH: Fluorometric assay for fleroxacin uptake by bacterial cells. Antimicrob Agents Chemother 1989;33:27-29.
33. Giraud E, Cloeckaert A, Kerboeuf D, Chaslus-Dancla E: Evidence of active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother 2000;44:1223-1228.
34. Ricci V, Piddock LJ: Accumulation of norfloxacin by Bacteroides fragilis. Antimicrob Agents Chemother 2000;44:2361-2366.
35. Rafii F, Park M: Effects of gyrase mutations on the growth kinetics of ciprofloxacin-resistant strains of Clostridium perfringens. Anaerobe 2005;11:201-205.